Ophthalmic Drugs Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

Published Date : Feb 2021 | No. of Pages : 250 Pages | Category : Healthcare


Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Ophthalmic Drugs Market, By Drug Class

7.1.  Ophthalmic Drugs Market, By Drug Class, 2020-2030

7.1.1.    Antiallergy

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    Anti-VEGF Agents

7.1.2.1.        Market Revenue and Forecast (2016-2030)

7.1.3.    Anti-inflammatory

7.1.3.1.        Market Revenue and Forecast (2016-2030)

7.1.4.    Antiglaucoma

7.1.4.1.        Market Revenue and Forecast (2016-2030)

7.1.5.    Others

7.1.5.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Ophthalmic Drugs Market, By Disease

8.1.  Ophthalmic Drugs Market, By Disease, 2020-2030

8.1.1.    Dry Eye

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    Eye Allergy

8.1.2.1.        Market Revenue and Forecast (2016-2030)

8.1.3.    Glaucoma

8.1.3.1.        Market Revenue and Forecast (2016-2030)

8.1.4.    Eye Infection

8.1.4.1.        Market Revenue and Forecast (2016-2030)

8.1.5.    Retinal Disorders

8.1.5.1.        Market Revenue and Forecast (2016-2030)

8.1.6.    Uveitis

8.1.6.1.        Market Revenue and Forecast (2016-2030)

8.1.7.    Others

8.1.7.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Ophthalmic Drugs Market, By Dosage Form Type

9.1.  Ophthalmic Drugs Market, By Dosage Form Type, 2020-2030

9.1.1.    Gels

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    Eye Solutions

9.1.2.1.        Market Revenue and Forecast (2016-2030)

9.1.3.    Capsules & Tablets

9.1.3.1.        Market Revenue and Forecast (2016-2030)

9.1.4.    Eye Drops

9.1.4.1.        Market Revenue and Forecast (2016-2030)

9.1.5.    Ointments

9.1.5.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Ophthalmic Drugs Market, By Route of Administration Type

10.1.        Ophthalmic Drugs Market, By Route of Administration Type, 2020-2030

10.1.1.  Topical

10.1.1.1.      Market Revenue and Forecast (2016-2030)

10.1.2.  Local Ocular

10.1.2.1.      Market Revenue and Forecast (2016-2030)

10.1.3.  Systemic

10.1.3.1.      Market Revenue and Forecast (2016-2030)

Chapter 11.      Global Ophthalmic Drugs Market, By Product Type

11.1.        Ophthalmic Drugs Market, By Product Type, 2020-2030

11.1.1.  Prescription Drugs

11.1.1.1.      Market Revenue and Forecast (2016-2030)

11.1.2.  OTC Drugs

11.1.2.1.      Market Revenue and Forecast (2016-2030)

Chapter 12.      Global Ophthalmic Drugs  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, By Drug Class type (2016-2030)

12.1.2.  Market Revenue and Forecast, By Disease Type (2016-2030)

12.1.3.  Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.1.4.  Market Revenue and Forecast, By Route of Administration (2016-2030)

12.1.5.  Market Revenue and Forecast, By Product Type (2016-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.1.6.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.1.6.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.1.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.1.7.  Market Revenue and Forecast, By Product Type (2016-2030)

12.1.8.  Rest of North America

12.1.8.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.1.8.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.1.8.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.1.8.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.1.8.5.      Market Revenue and Forecast, By Product Type (2016-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, By Drug Class type (2016-2030)

12.2.2.  Market Revenue and Forecast, By Disease Type (2016-2030)

12.2.3.  Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.2.4.  Market Revenue and Forecast, By Route of Administration (2016-2030)

12.2.5.  Market Revenue and Forecast, By Product Type (2016-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.2.6.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.2.6.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.2.7.  Market Revenue and Forecast, By Route of Administration (2016-2030)

12.2.8.  Market Revenue and Forecast, By Product Type (2016-2030)

12.2.9.  Germany

12.2.9.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.2.9.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.2.9.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.2.10.               Market Revenue and Forecast, By Route of Administration (2016-2030)

12.2.11.               Market Revenue and Forecast, By Product Type (2016-2030)

12.2.12.               France

12.2.12.1.   Market Revenue and Forecast, By Drug Class type (2016-2030)

12.2.12.2.   Market Revenue and Forecast, By Disease Type (2016-2030)

12.2.12.3.   Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.2.12.4.   Market Revenue and Forecast, By Route of Administration (2016-2030)

12.2.13.               Market Revenue and Forecast, By Product Type (2016-2030)

12.2.14.               Rest of Europe

12.2.14.1.   Market Revenue and Forecast, By Drug Class type (2016-2030)

12.2.14.2.   Market Revenue and Forecast, By Disease Type (2016-2030)

12.2.14.3.   Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.2.14.4.   Market Revenue and Forecast, By Route of Administration (2016-2030)

12.2.15.               Market Revenue and Forecast, By Product Type (2016-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, By Drug Class type (2016-2030)

12.3.2.  Market Revenue and Forecast, By Disease Type (2016-2030)

12.3.3.  Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.3.4.  Market Revenue and Forecast, By Route of Administration (2016-2030)

12.3.5.  Market Revenue and Forecast, By Product Type (2016-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.3.6.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.3.6.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.3.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.3.7.  Market Revenue and Forecast, By Product Type (2016-2030)

12.3.8.  China

12.3.8.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.3.8.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.3.8.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.3.8.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.3.9.  Market Revenue and Forecast, By Product Type (2016-2030)

12.3.10.               Japan

12.3.10.1.   Market Revenue and Forecast, By Drug Class type (2016-2030)

12.3.10.2.   Market Revenue and Forecast, By Disease Type (2016-2030)

12.3.10.3.   Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.3.10.4.   Market Revenue and Forecast, By Route of Administration (2016-2030)

12.3.10.5.   Market Revenue and Forecast, By Product Type (2016-2030)

12.3.11.               Rest of APAC

12.3.11.1.   Market Revenue and Forecast, By Drug Class type (2016-2030)

12.3.11.2.   Market Revenue and Forecast, By Disease Type (2016-2030)

12.3.11.3.   Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.3.11.4.   Market Revenue and Forecast, By Route of Administration (2016-2030)

12.3.11.5.   Market Revenue and Forecast, By Product Type (2016-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, By Drug Class type (2016-2030)

12.4.2.  Market Revenue and Forecast, By Disease Type (2016-2030)

12.4.3.  Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.4.4.  Market Revenue and Forecast, By Route of Administration (2016-2030)

12.4.5.  Market Revenue and Forecast, By Product Type (2016-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.4.6.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.4.6.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.4.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.4.7.  Market Revenue and Forecast, By Product Type (2016-2030)

12.4.8.  North Africa

12.4.8.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.4.8.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.4.8.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.4.8.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.4.9.  Market Revenue and Forecast, By Product Type (2016-2030)

12.4.10.               South Africa

12.4.10.1.   Market Revenue and Forecast, By Drug Class type (2016-2030)

12.4.10.2.   Market Revenue and Forecast, By Disease Type (2016-2030)

12.4.10.3.   Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.4.10.4.   Market Revenue and Forecast, By Route of Administration (2016-2030)

12.4.10.5.   Market Revenue and Forecast, By Product Type (2016-2030)

12.4.11.               Rest of MEA

12.4.11.1.   Market Revenue and Forecast, By Drug Class type (2016-2030)

12.4.11.2.   Market Revenue and Forecast, By Disease Type (2016-2030)

12.4.11.3.   Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.4.11.4.   Market Revenue and Forecast, By Route of Administration (2016-2030)

12.4.11.5.   Market Revenue and Forecast, By Product Type (2016-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, By Drug Class type (2016-2030)

12.5.2.  Market Revenue and Forecast, By Disease Type (2016-2030)

12.5.3.  Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.5.4.  Market Revenue and Forecast, By Route of Administration (2016-2030)

12.5.5.  Market Revenue and Forecast, By Product Type (2016-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.5.6.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.5.6.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.5.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.5.7.  Market Revenue and Forecast, By Product Type (2016-2030)

12.5.8.  Rest of LATAM

12.5.8.1.      Market Revenue and Forecast, By Drug Class type (2016-2030)

12.5.8.2.      Market Revenue and Forecast, By Disease Type (2016-2030)

12.5.8.3.      Market Revenue and Forecast, By Dosage Form Type (2016-2030)

12.5.8.4.      Market Revenue and Forecast, By Route of Administration (2016-2030)

12.5.8.5.      Market Revenue and Forecast, By Product Type (2016-2030)

Chapter 13.  Company Profiles

13.1.              Alcon

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              Johnson & Johnson Services, Inc.

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              Bausch Health

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              Allergan

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              Pfizer, Inc.

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Bayer AG

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              Santen Pharmaceutical Co. Ltd.

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              Genentech, Inc.

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              Novartis AG.

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Regeneron

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

13.11.           Merck & Co.

13.11.1.               Company Overview

13.11.2.               Product Offerings

13.11.3.               Financial Performance

13.11.4.               Recent Initiatives

13.12.           Coherus Biosciences, Inc.

13.12.1.               Company Overview

13.12.2.               Product Offerings

13.12.3.               Financial Performance

13.12.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

Glossary of Terms

Featured Research Reports

  • Featured Research Reports

    Cancer Supportive Care Drugs Market (By Therapeutic Class: G-CSFs, Anti-emetics, ESAs, Bisphosphonates, Opioids, NSAIDs & Others)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    eHealth Devices Market( By Type: Blood Pressure Meters, Fever Meters, Glucose Meters, Care Phone/Social Alarms)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    Tracheostomy Products Market (By Demographics: Adults, Paediatrics/Neonatal; By Type: Tracheostomy Tubes, Ventilation Accessories ; By End Use: Hospitals & Surgery Centers, Ambulatory Care Centers, Home Care Settings, Others; By Technique) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    Smart Blood Pressure Monitoring Devices Market (By Type: Upper Arm Blood Pressure Monitor, Wrist Blood Pressure Monitor Finger Blood Pressure Monitor; By Technology: Wi-Fi Based/4G, Bluetooth Based)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...
  • Featured Research Reports

    Laparoscopic Electrodes Market (By Application: Bariatric, General Surgeries; By Product: Monopolar, Bipolar Electrodes; By End User: Hospital, Ambulatory)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

    Read more...